Fig. 1From: Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort studyApplication of selection criteria and patient disposition. AS ankylosing spondylitis, Hx history, IBD inflammatory bowel disease, ILD interstitial lung disease, PA psoriatic arthritis, RA rheumatoid arthritisBack to article page